Lion Point Capital, LP Q2 2025 Filing

Filed August 14, 2025

Portfolio Value

$14.7B

Holdings

19

Report Date

Q2 2025

Filing Type

13F-HR

All Holdings (19 positions)

#StockSharesValue% PortfolioType
1
FRXFENNEC PHARMACEUTICALS INC
195,700$1.6B11.03%
2
ARDXARDELYX INC
335,400$1.3B8.93%
3
KNSAKINIKSA PHARMACEUTICALS INTL
45,900$1.3B8.62%
4
BBIOBRIDGEBIO PHARMA INC
26,000$1.1B7.62%
5
IM8NINSMED INC
10,650$1.1B7.28%
6
MLYSMINERALYS THERAPEUTICS INC
79,000$1.1B7.26%
7
MISTMILESTONE PHARMACEUTICALS IN
548,806$1.1B7.23%
8
AVDLAVADEL PHARMACEUTICALS PLC
98,700$873.5M5.93%
9
JSPRJASPER THERAPEUTICS INC
146,500$813.1M5.52%
10
BNTCBENITEC BIOPHARMA INC
62,000$725.4M4.93%
11
GONGERON CORP
500,000$705.0M4.79%
12
ARQTARCUTIS BIOTHERAPEUTICS INC
46,300$649.1M4.41%
13
IRONDISC MEDICINE INC
10,600$561.4M3.81%
14
SNDXSYNDAX PHARMACEUTICALS INC
55,000$515.1M3.50%
15
RGNXREGENXBIO INC
57,750$474.1M3.22%
16
BHVNBIOHAVEN LTD
22,700$320.3M2.17%
17
MERSANA THERAPEUTICS INC
644,000$190.6M1.29%
18
MCRBSERES THERAPEUTICS INC
17,038$189.3M1.29%
19
HUMAHUMACYTE INC
83,500$174.5M1.18%